Telehealth company Hims & Hers Health (NYSE: HIMS) will be reporting results this Monday after market hours. Here’s what to expect.

Hims & Hers Health beat analysts’ revenue expectations by 8.3% last quarter, reporting revenues of $586 million, up 111% year on year. It was a strong quarter for the company, with a solid beat of analysts’ EPS estimates and full-year EBITDA guidance beating analysts’ expectations. It added 137,000 customers to reach a total of 2.37 million.

Is Hims & Hers Health a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Hims & Hers Health’s revenue to grow 74.5% year on year to $550.8 million, improving from the 51.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.23 per share.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hims & Hers Health has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 3.2% on average.

Looking at Hims & Hers Health’s peers in the healthcare technology segment, only Omnicell has reported results so far. It beat analysts’ revenue estimates by 4.9%, delivering year-on-year sales growth of 5%. The stock price was unchanged following the results.

Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Hims & Hers Health is up 29% during the same time and is heading into earnings with an average analyst price target of $48.36 (compared to the current share price of $62.48).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.